Skip to Content

Shi-Ming Tu, MD

Present Title & Affiliation

Primary Appointment

Professor, Department of Genitourinary Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX

Office Address

The University of Texas MD Anderson Cancer Center
1155 Pressler Street
Unit Number: 1374
Houston, TX 77030
Room Number: CPB7.3468
Phone: (713) 792-2830
Fax: (713) 745-1625

Education & Training

Degree-Granting Education

1987 Washington University, St. Louis, MO, MD, Medicine
1982 The John Hopkins University, Baltimore, MD, BA, Chemistry

Postgraduate Training

1990-1993 Clinical Fellowship, Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX
1987-1990 Residency in Internal Medicine, University of Illinois Hospitals, Chicago, IL

Board Certifications

7/1988 Diplomate, National Board of Medical Examiners


Academic Appointments

Associate Professor, Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, 9/2002-9/2012
Assistant Professor, Department of Genitourinary Medical Oncology, Division of Cancer Medicine, The University of Texas M. D. Anderson Cancer Center, Houston, TX, 9/1995-8/2002
Instructor, Department of Genitourinary Medical Oncology, Division of Cancer Medicine, The University of Texas M. D. Anderson Cancer Center, Houston, TX, 9/1993-8/1995

Honors and Awards

2001 Americas Registry of Outstanding Professionals
1993 University Cancer Foundation Research Award
1993 Upjohn Research Award

Selected Publications

Peer-Reviewed Original Research Articles

1. Bilen MA, Johnson MM, Mathew P, Pagliaro LC, Araujo JC, Aparicio A, Corn PG, Tannir NM, Wong FC, Fisch MJ, Logothetis CJ, Tu SM. Randomized phase 2 study of bone-targeted therapy containing strontium-89 in advanced castrate-sensitive prostate cancer. Cancer 121(1):69-76, 1/2015. PMCID: PMC4270821.
2. Tu SM, Bilen MA, Tannir NM. The scientific method: pillar and pitfall of cancer research. Cancer Med 3(4):1035-7, 8/2014. e-Pub 4/8/2014. PMCID: PMC4303171.
3. Bilen MA, Hariri H, Leon C. Guo CC, Kuban DA, Pister LL, Tu SM. Positive FDG-PET/CT scans of a residual seminoma after chemotherapy and radiotherapy: case report and review of the literature. Clin Genitourin Cancer 12(4). e-Pub 2/2014. PMCID: PMC4104212.
4. Som A, Wen S, Tu SM. Stem cell origin of testicular seminoma. Clin Genitourin Cancer 11(4):489-94, 12/2013. e-Pub 7/2013. PMCID: PMC3834099.
5. Aparicio AM, Harzstark A, Corn PG, Wen S, Araujo J, Tu SM, Pagliaro L, Kim J, Millikan RE, Ryan CJ, Tannir NM, Zurita A, Mathew P, Arap W, Troncoso P, Thall P, Logothetis CJ. Platinum-Based Chemotherapy for Variant Castrate-Resistant Prostate Cancer. Clin Cancer Res 19(13):3621-30, 7/2013. PMCID: PMC3699964.
6. Bilen MA, Kim J, Wang H, Tu SM. Cixutumumab-Associated Pancolitis in a Patient With Prostate Cancer. Clin Genitourin Cancer 11(2):207-10, 6/2013. PMCID: PMC3579009.
7. Tu SM. Cancer: a "stem-cell" disease? Cancer Cell Int 13(1):40, 5/2013. PMCID: PMC3651409.
8. Rodney AJ, Tannir NM, Siefker-Radtke AO, Liu P, Walsh GL, Millikan RE, Swisher SG, Tu SM, Pagliaro LC. Survival outcomes for men with mediastinal germ-cell tumors: The University of Texas M. D. Anderson Cancer Center experience. Urol Oncol 30(6):879-85, 12/2012. PMCID: PMC3956468.
9. Som A, Tu SM, Liu J, Wang X, Qiao W, Logothetis C, Corn PG. Response in bone turnover markers during therapy predicts overall survival in patients with metastatic prostate cancer: analysis of three clinical trials. Br J Cancer 107(9):1547-53, 10/2012. PMCID: PMC23033003.
10. Tu SM, Som A, Tu B, Logothetis CJ, Lee MH, Yeung SC. Effect of paget's disease of bone (osteitis deformans) on the progression of prostate cancer bone metastasis. Br J Cancer 107(4):646-51, 8/2012. PMCID: PMC3419961.
11. Som A, Zhu R, Guo CC, Efstathiou E, Xiao L, Pisters LL, Matin A, Tu SM. Recurrent seminomas: Clinical features and biologic implications. Urol Oncol 30(4):494-501, 8/2012. PMCID: PMC3856193.
12. Tu SM, Lin SH. Prostate cancer stem cells. Clin Genitourin Cancer 10(2):69-76, 6/2012. e-Pub 3/2012. PMCID: PMC4141775.
13. Tu SM, Chen AH. Re: Positive effects of zoledronate on skeletal-related events in patients with renal cell cancer and bone metastases. Can J Urol 19(3):6268, 6/2012. PMID: 22704311.
14. Yennurajalingam S, Atkinson B, Masterson J, Hui D, Urbauer D, Tu SM, Bruera E. The impact of an outpatient palliative care consultation on symptom burden in advanced prostate cancer patients. J Palliat Med 15(1):20-4, 1/2012. e-Pub 12/5/2011. PMID: 22141432.
15. Manoukian GE, Tannir NM, Jonasch E, Qiao W, Haygood TM, Tu SM. Pilot trial of bone-targeted therapy combining zoledronate with fluvastatin or atorvastatin for patients with metastatic renal cell carcinoma. Clin Genitourin Cancer 9(2):81-8, 12/2011. PMCID: PMC3641665.
16. Bilen MA, General R, Tu SM. Prolonged remission of fulminant castrate-resistant prostate cancer: a case report. Clin Genitourin Cancer 9(2):133-6, 12/2011. PMCID: PMC3221513.
17. He XX, Tu SM, Lee MH, Yeung SC. Thiazolidinediones and metformin associated with improved survival of diabetic prostate cancer patients. Ann Oncol 22(12):2640-5, 12/2011. PMCID: PMC3221513.
18. Atkinson BJ, Tu SM. Radiopharmaceuticals: present and future. J Support Oncol 9(6):206-7, Nov-Dec, 11/2011. PMID: 22005215.
19. Staquicini FI, Cardó-Vila M, Kolonin MG, Trepel M, Edwards JK, Nunes DN, Sergeeva A, Efstathiou E, Sun J, Almeida NF, Tu SM, Botz GH, Wallace MJ, O'Connell DJ, Krajewski S, Gershenwald JE, Molldrem JJ, Flamm AL, Koivunen E, Pentz RD, Dias-Neto E, Setubal JC, Cahill DJ, Troncoso P, Do KA, Logothetis CJ, Sidman RL, Pasqualini R, Arap W. Vascular ligand-receptor mapping by direct combinatorial selection in cancer patients. Proc Natl Acad Sci U S A 108(46):18637-42, 11/2011. PMID: 22049339.
20. Mathew P, Tannir N, Tu SM, Wen S, Guo CC, Marcott V, Bekele BN, Pagliaro L. Accelerated disease progression in prostate cancer and bone metastases with platelet-derived growth factor receptor inhibition: observations with tandutinib. Cancer Chemother Pharmacol 68(4):889-96, 10/2011. PMID: 21290244.
21. Contreras AL, Punar M, Tamboli P, Tu SM, Pisters L, Moran C, Czerniak BA, Guo CC. Mediastinal germ cell tumors with an angiosarcomatous component: a report of 12 cases. Hum Pathol 41(6):832-7, 6/2010. e-Pub 2/2010. PMID: 20153508.
22. Mathew P, Tannir N, Tu SM, Carter CM, Bekele NB, Pagliaro L. A modular Phase 1 study of lenalidomide and paclitaxel in metastatic castration-resistant prostate cancer following prior taxane therapy. Cancer Chemother Pharmacol 65(4):811-5, 3/2010. e-Pub 1/6/2010. PMID: 20052472.
23. Taplin ME, Regan MM, Ko YJ, Bubley GJ, Duggan SE, Werner L, Beer TM, Ryan CW, Mathew P, Tu SM, Denmeade SR, Oh WK, Sartor O, Mantzoros CS, Rittmaster R, Kantoff PW, Balk SP. "Phase II study of androgen synthesis inhibition with ketoconazole, hydrocortison and dutasteride (KHAD) in asymptomatic castration resistant prostate cancer". Clin Cancer Res 15(22):7099-105, 11/15/2009. e-Pub 11/3/2009. PMID: 19887483.
24. Jonasch E, Wood CG, Matin SF, Tu SM, Pagliaro LC, Corn PG, Aparicio A, Tamboli P, Millikan RE, Wang X, Araujo JC, Arap W, Tannir N. Phase II presurgical feasibility study of bevacizumab in untreated patients with metastatic renal cell carcinoma. J Clin Oncol 27(25):4076-81, 9/1/2009. e-Pub 7/27/2009. PMID: 19636008.
25. Guo CC, Punar M, Contreras AL, Tu SM, Pisters L, Tamboli P, Czerniak B. Testicular germ cell tumors with sarcomatous components: an analysis of 33 cases. Am J Surg Pathol 33(8):1173-8, 8/2009. PMID: 19561445.
26. Tu SM, Lopez A, Leibovici D, Bilen MA, Evliyaoglu F, Aparicio A, Guo CC, Kuban DA, Johnson MM, Pisters LL. Ductal Adenocarcinoma of the Prostate - Clinical Features and Implications after Local Therapy. Cancer 115(13):2872-80, 7/1/2009. e-Pub 4/2009. PMID: 19402048.
27. Tu SM, Mathew P, Wong FC, Jones D, Johnson MM, Logothetis CJ. Phase I Study of Concurrent Weekly Docetaxel and Repeated Samarium-153 Lexidronam in Patients With Castration-Resistant Metastatic Prostate Cancer. J Clin Oncol 27(20):3319-24, 7/10/2009. e-Pub 5/4/2009. PMID: 19414670.
28. Williams BJ, Fox BD, Sciubba DM, Suki D, Tu SM, Kuban D, Gokaslan ZL, Rhines LD, Rao G. Surgical management of prostate cancer metastatic to the spine. J Neurosurg Spine 10(5):414-22, 5/2009. PMID: 19442002.
29. Svatek RS, Spiess PE, Sundi D, Tu SM, Tannir NM, Brown GA, Kamat AM, Wood CG, Pisters LL. Long-term outcome for men with teratoma found at postchemotherapy retroperitoneal lymph node dissection. Cancer 115(6):1310-7, 3/15/2009. PMID: 19156903.
30. Gnjatic S, Altorki NK, Tang DN, Tu SM, Kundra V, Ritter G, Old LJ, Logothetis CJ, Sharma P. NY-ESO-1 DNA Vaccine Induces T Cell Responses that are Suppressed by Regulatory T Cells. Clin Cancer Res 15(6):2130-9, 3/15/2009. e-Pub 3/10/2009. PMID: 19276258.
31. Lin SH, Cheng CJ, Lee YC, Ye X, Tsai WW, Kim J, Pasqualini R, Arap W, Navone NM, Tu SM, Hu M, Yu-Lee LY, Logothetis CJ. A 45-kDa ErbB3 secreted by prostate cancer cells promotes bone formation. Oncogene 27(39):5195-203, 9/4/2008. e-Pub 5/19/2008. PMCID: PMC2562662.
32. Bilen MA, Waguespack SG, Tannir NM, Pravinkumar SE, Tamboli P, Tu SM. Multisystem crisis in a patient with presumptive renal cell carcinoma. Clin Genitourin Cancer 6(2):128-30, 9/2008. PMID: 18824438.
33. Lin SH, Lee YC, Choueiri MB, Wen S, Mathew P, Ye X, Do KA, Navone NM, Kim J, Tu SM, Yu-Lee LY, Logothetis CJ. Soluble ErbB3 levels in bone marrow and plasma of men with prostate cancer. Clin Cancer Res 14(12):3729-36, 6/15/2008. PMCID: PMC2562877.
34. Jonasch E, Wood C, Tamboli P, Pagliaro LC, Tu SM, Kim J, Srivastava P, Perez C, Isakov L, Tannir N. Vaccination of metastatic renal cell carcinoma patients with autologous tumour-derived vitespen vaccine: clinical findings. Br J Cancer 98(8):1336-41, 4/22/2008. e-Pub 3/25/2008. PMCID: PMC2361701.
35. Spiess PE, Tannir NM, Tu SM, Brown GA, Liu P, Kamat AM, Wood CG, Evans JG, Pisters LL. Viable germ cell tumor at postchemotherapy retroperitoneal lymph node dissection: can we predict patients at risk of disease progression? Cancer 110(12):2700-8, 12/15/2007. PMID: 17948916.
36. Spiess PE, Tannir NM, Brown GA, Liu P, Tu SM, Evans JG, Pisters LL. Recurrence in nonseminomatous germ cell testis tumor patients with no viable tumor at postchemotherapy retroperitoneal lymph node dissection. Urology 70(6):1173-8, 12/2007. PMID: 18158041.
37. Mathew P, Thall PF, Bucana CD, Oh WK, Morris MJ, Jones DM, Johnson MM, Wen S, Pagliaro LC, Tannir NM, Tu SM, Meluch AA, Smith L, Cohen L, Kim SJ, Troncoso P, Fidler IJ, Logothetis CJ. Platelet-derived growth factor receptor inhibition and chemotherapy for castration-resistant prostate cancer with bone metastases. Clin Cancer Res 13(19):5816-24, 10/1/2007. PMID: 17908974.
38. Lin PP, Mirza AN, Lewis VO, Cannon CP, Tu SM, Tannir NM, Yasko AW. Patient survival after surgery for osseous metastases from renal cell carcinoma. J Bone Joint Surg Am 89(8):1794-801, 8/2007. PMID: 17671020.
39. Cheng CJ, Ye XC, Vakar-Lopez F, Kim J, Tu SM, Chen DT, Navone NM, Yu-Lee LY, Lin SH, Hu MC. Bone microenvironment and androgen status modulate subcellular localization of ErbB3 in prostate cancer cells. Mol Cancer Res 5(7):675-84, 7/2007. PMCID: PMC2000833.
40. Lin BY, Chao TH, Yao Y, Tu SM, Wu CC, Chern JY, Chao SH, Shaw KY. How can activity-based costing methodology be performed as a powerful tool to calculate costs and secure appropriate patient care? J Med Syst 31(2):85-90, 4/2007. PMID: 17489499.
41. Kopetz S, Jimenez C, Tu SM, Sharma P. Pulmonary arteriovenous fistula in a patient with renal cell carcinoma. Eur Respir J 29(4):813-5, 4/2007. PMID: 17400880.
42. Spiess PE, Kassouf W, Brown GA, Kamat AM, Liu P, Gomez JA, Tu SM, Tannir NM, Pisters LL. Surgical management of growing teratoma syndrome: the M. D. Anderson cancer center experience. J Urol 177(4):1330-4; discussion 1334, 4/2007. PMID: 17382725.
43. Leibovici D, Spiess PE, Agarwal PK, Tu SM, Pettaway CA, Hitzhusen K, Millikan RE, Pisters LL. Prostate cancer progression in the presence of undetectable or low serum prostate-specific antigen level. Cancer 109(2):198-204, 1/15/2007. PMID: 17171704.
44. Tuziak T, Spiess PE, Abrahams NA, Wrona A, Tu SM, Czerniak B. Multilocular cystadenoma and cystadenocarcinoma of the prostate. Urol Oncol 25(1):19-25, Jan-Feb, 1/2007. PMID: 17208134.
45. Spiess PE, Brown GA, Liu P, Tu SM, Tannir NM, Evans JG, Kamat AM, Kassouf W, Pisters LL. Recurrence pattern and proposed surveillance protocol following post-chemotherapy retroperitoneal lymph node dissection. J Urol 177(1):131-8, 1/2007. PMID: 17162023.
46. Pagliaro LC, Perez CA, Tu SM, Daliani DD. Phase II study of capecitabine single-agent therapy in patients with metastatic renal cell carcinoma. Urol Oncol 24(6):487-91, Nov-Dec, 11/2006. PMID: 17138128.
47. Spiess PE, Brown GA, Liu P, Tannir NM, Tu SM, Evans JG, Czerniak B, Kamat AM, Pisters LL. Predictors of outcome in patients undergoing postchemotherapy retroperitoneal lymph node dissection for testicular cancer. Cancer 107(7):1483-90, 10/1/2006. PMID: 16944541.
48. Spiess PE, Brown GA, Pisters LL, Liu P, Tu SM, Evans JG, Kamat AM, Black P, Tannir NM. Viable malignant germ cell tumor in the postchemotherapy retroperitoneal lymph node dissection specimen: can it be predicted using clinical parameters? Cancer 107(7):1503-10, 10/1/2006. PMID: 16944534.
49. Tannir N, Jonasch E, Pagliaro LC, Mathew P, Siefker-Radtke A, Rhines L, Lin P, Tibbs R, Do KA, Lin SH, Tu SM. Pilot trial of bone-targeted therapy with zoledronate, thalidomide, and interferon-gamma for metastatic renal cell carcinoma. Cancer 107(3):497-505, 8/1/2006. PMID: 16795067.
50. Tu SM, Kim J, Pagliaro LC, Vakar-Lopez F, Wong FC, Wen S, General R, Podoloff DA, Lin SH, Logothetis CJ. Therapy tolerance in selected patients with androgen-independent prostate cancer following strontium-89 combined with chemotherapy. J Clin Oncol 23(31):7904-10, 11/1/2005. PMID: 16258090.
51. Papandreou CN, Daliani DD, Nix D, Yang H, Madden T, Wang X, Pien CS, Millikan RE, Tu SM, Pagliaro L, Kim J, Adams J, Elliott P, Esseltine D, Petrusich A, Dieringer P, Perez C, Logothetis CJ. Phase I trial of the proteasome inhibitor bortezomib in patients with advanced solid tumors with observations in androgen-independent prostate cancer. J Clin Oncol 22(11):2108-21, 6/1/2004. PMID: 15169797.
52. Vakar-Lopez F, Cheng CJ, Kim J, Shi GG, Troncoso P, Tu SM, Yu-Lee LY, Lin SH. Up-regulation of MDA-BF-1, a secreted isoform of ErbB3, in metastatic prostate cancer cells and activated osteoblasts in bone marrow. J Pathol 203(2):688-95, 6/2004. PMID: 15141384.
53. Tu SM, Millikan RE, Pagliaro LC, Daliani D, Papandreou CN, Kim J, Chen DT, Williams DL, Logothetis CJ. Treatment of refractory urothelial carcinoma with alternating paclitaxel, methotrexate, cisplatin (TMP) and 5-fluorouracil, alpha-interferon, cisplatin (FAP). Urol Oncol 21(5):342-8, Sep-Oct, 9/2003. PMID: 14670540.
54. Esmaeli B, Hidaji L, Adinin RB, Faustina M, Coats C, Arbuckle R, Rivera E, Valero V, Tu SM, Ahmadi MA. Blockage of the lacrimal drainage apparatus as a side effect of docetaxel therapy. Cancer 98(3):504-7, 8/1/2003. PMID: 12879466.
55. Pagliaro LC, Delpassand ES, Williams D, Millikan RE, Tu SM, Logothetis CJ. A Phase I/II study of strontium-89 combined with gemcitabine in the treatment of patients with androgen independent prostate carcinoma and bone metastases. Cancer 97(12):2988-94, 6/15/2003. PMID: 12784333.
56. Daliani DD, Assikis V, Tu SM, Papandreou CN, Pagliaro LC, Holtkamp T, Wang X, Thall PF, Logothetis CJ. Phase II trial of cyclophosphamide, vincristine, and dexamethasone in the treatment of androgen-independent prostate carcinoma. Cancer 97(3):561-7, 2/1/2003. PMID: 12548597.
57. Kim J, Millikan RE, Smith TL, Tu SM, Pagliaro LC, Logothetis CJ. Treating refractory advanced or metastatic urothelial carcinoma with interleukin-2: a phase II study. Urol Oncol 21(1):21-6, Jan-Feb, 1/2003. PMID: 12684123.
58. Tu SM, Lin SH, Logothetis CJ. Stem-cell origin of metastasis and heterogeneity in solid tumours. Lancet Oncol 3(8):508-13, 8/2002. PMID: 12147437.
59. Pagliaro LC, Millikan RE, Tu SM, Williams D, Daliani D, Papandreou CN, Logothetis CJ. Cisplatin, gemcitabine, and ifosfamide as weekly therapy: a feasibility and phase II study of salvage treatment for advanced transitional-cell carcinoma. J Clin Oncol 20(13):2965-70, 7/1/2002. PMID: 12089226.
60. Papandreou CN, Daliani DD, Thall PF, Tu SM, Wang X, Reyes A, Troncoso P, Logothetis CJ. Results of a Phase II Study with Doxorubicin, Etoposide, and Cisplatin in Patients with Fully Characterized Small-Cell Carcinoma of the Prostate. J Clin Oncol 20(14):3072-3080, 7/15/2002. PMID: 12118020.
61. Fizazi K, Prow DM, Do KA, Wang X, Finn L, Kim J, Daliani D, Papandreou CN, Tu SM, Millikan RE, Pagliaro LC, Logothetis CJ, Amato RJ. Alternating dose-dense chemotherapy in patients with high volume disseminated non-seminomatous germ cell tumours. Br J Cancer 86(10):1555-60, 5/20/2002. PMCID: PMC2746595.
62. Tu SM, Reyes A, Maa A, Bhowmick D, Pisters LL, Pettaway CA, Lin SH, Troncoso P, Logothetis CJ. Prostate carcinoma with testicular or penile metastases. Clinical, pathologic, and immunohistochemical features. Cancer 94(10):2610-7, 5/15/2002. PMID: 12173328.
63. Siefker-Radtke AO, Millikan RE, Tu SM, Moore DF, Smith TL, Williams D, Logothetis CJ. Phase III trial of fluorouracil, interferon alpha-2b, and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in metastatic or unresectable urothelial cancer. J Clin Oncol 20(5):1361-7, 3/1/2002. PMID: 11870180.
64. Sexton WJ, Lance RE, Reyes AO, Pisters PW, Tu SM, Pisters LL. Adult prostate sarcoma: the M.D. Anderson Cancer Center Experience. J Urol 166(2):521-5, 8/2001. PMID: 11458058.
65. Tu SM, Millikan RE, Mengistu B, Delpassand ES, Amato RJ, Pagliaro LC, Daliani D, Papandreou CN, Smith TL, Kim J, Podoloff DA, Logothetis CJ. Bone-targeted therapy for advanced androgen-independent carcinoma of the prostate a randomised phase II trial. Lancet 357(9253):336-41, 2/3/2001. PMID: 11210994.
66. Park DS, Vassilopoulou Sellin R, Tu SM. Estramustine-related hypocalcemia in patients with prostate carcinoma and osteoblastic metastases. Urology 58(1):105, 2001. PMID: 11445494.
67. Pagliaro L, Daliani D, Amato R, Tu SM, Jones D, Smith T, Logothetis C, Millikan R. A Phase II trial of bryostatin-1 for patients with metastatic renal cell carcinoma. Cancer 89(3):615-8, 8/1/2000. PMID: 10931461.
68. Beham AW, Sarkiss M, Brisbay S, Tu SM, von Eschenbach AC, McDonnell TJ. Molecular correlates of bcl-2-enhanced growth following androgen-ablation in prostate carcinoma cells in vivo. Int J Mol Med 1(6):953-9, 6/1998. PMID: 9852630.
69. Tu SM, Pagliaro LC, Banks ME, Amato RJ, Millikan RE, Bugazia NA, Madden T, Newman RA, Logothetis CJ. Phase I study of suramin combined with doxorubicin in the treatment of androgen-independent prostate cancer. Clin Cancer Res 4(5):1193-201, 5/1998. e-Pub 5/1998. PMID: 9607577.
70. Westney OL, Pisters LL, Pettaway CA, Tu SM, Pollack A, Dinney CP. Presentation, methods of diagnosis and therapy for pelvic recurrence following radical cystectomy for transitional cell carcinoma of the bladder. J Urol 159(3):792-5, 3/1998. PMID: 9474150.
71. Ellerhorst JA, Sella A, Amato RJ, Tu SM, Millikan RE, Finn LD, Banks M, Logothetis CJ. Phase II trial of 5-fluorouracil, interferon-alpha and continuous infusion interleukin-2 for patients with metastatic renal cell carcinoma. Cancer 80(11):2128-32, 12/1/1997. PMID: 9392335.
72. Navone NM, Olive M, Ozen M, Davis R, Troncoso P, Tu SM, Johnston D, Pollack A, Pathak S, von Eschenbach AC, Logothetis CJ. Establishment of two human prostate cancer cell lines derived from a single bone metastasis. Clin Cancer Res 3(12 Pt 1):2493-500, 12/1997. PMID: 9815652.
73. DeLima M, Amato RJ, Jackson A, Tu SM, Banks M, Finn L, Ellerhorst J. Phase I-II study of gamma interferon and 5-fluorouracil for patients with metastatic renal cell carcinoma. Cancer Biother Radiopharm 12(6):365-70, 12/1997. PMID: 10851489.
74. Ellerhorst JA, Tu SM, Amato RJ, Finn L, Millikan RE, Pagliaro LC, Jackson A, Logothetis CJ. Phase II trial of alternating weekly chemohormonal therapy for patients with androgen-independent prostate cancer. Clin Cancer Res 3(12 Pt 1):2371-6, 12/1997. PMID: 9815636.
75. Tu SM, Delpassand ES, Jones D, Amato RJ, Ellerhorst J, Logothetis CJ. Strontium-89 combined with doxorubicin in the treatment of patients with androgen-independent prostate cancer. Urol Oncol 2(6):191-7, Nov-Dec, 11/1996. PMID: 21224168.
76. Tu SM, Hossan E, Amato R, Kilbourn R, Logothetis CJ. Paclitaxel, cisplatin and methotrexate combination chemotherapy is active in the treatment of refractory urothelial malignancies. J Urol 154(5):1719-22, 11/1995. e-Pub 9/1995. PMID: 7563331.
77. Logothetis CJ, Finn LD, Smith T, Kilbourn RG, Ellerhorst JA, Zukiwski AA, Sella A, Tu SM, Amato RJ. Escalated MVAC with or without recombinant human granulocyte-macrophage colony-stimulating factor for the initial treatment of advanced malignant urothelial tumors: results of a randomized trial. J Clin Oncol 13(9):2272-7, 9/1995. PMID: 7666085.
78. Tu SM, McConnell K, Marin MC, Campbell ML, Fernandez A, von Eschenbach AC, McDonnell TJ. Combination adriamycin and suramin induces apoptosis in bcl-2 expressing prostate carcinoma cells. Cancer Lett 93(2):147-55, 7/13/1995. PMID: 7621422.
79. Tu SM, Robinson ED, Amato RJ, Ellerhorst JA, Kilbourn RG, Logothetis CJ. A phase I study of FAP (5-Fluorouracil, a-interferon and cisplatin) combined with methotrexate for the treatment of advanced urothelial malignancies. Urol Oncol 1(4):156-60, Jul-Aug, 7/1995. PMID: 21224110.
80. McDonnell TJ, Marin MC, Hsu B, Brisbay SM, McConnell K, Tu SM, Campbell ML, Rodriguez-Villanueva J. The bcl-2 oncogene: apoptosis and neoplasia. Radiat Res 136(3):307-12, 12/1993. PMID: 8278571.
81. McDonnell TJ, Troncoso P, Brisbay SM, Logothetis C, Chung LW, Hsieh JT, Tu SM, Campbell ML. Expression of the protooncogene bcl-2 in the prostate and its association with emergence of androgen-independent prostate cancer. Cancer Res 52(24):6940-4, 12/15/1992. PMID: 1458483.
82. Deckmyn H, Tu SM, Majerus PW. Guanine nucleotides stimulate soluble phosphoinositide-specific phospholipase C in the absence of membranes. J Biol Chem 261(35):16553-8, 12/15/1986. PMID: 3023354.

Invited Articles

1. Tu SM, Lin SH, Podoloff DA, Logothetis CJ. Multimodality Therapy: Bone-Targeted Radioisotope Therapy of Prostate Cancer. Clin Adv Hematol Oncol 8(5):341-51, 5/2010. PMID: 20551894.
2. Tu SM, Lin SH. Current trials using bone-targeting agents in prostate cancer. Cancer J 14(1):199, Jan-Feb, 1/2008. PMID: 18303481.
3. Ye XC, Choueiri M, Tu SM, Lin SH. Biology and clinical management of prostate cancer bone metastasis. Front Biosci 12:3273-86, 2007. PMID: 17485298.
4. Choueiri MB, Tu SM, Yu-Lee LY, Lin SH. The central role of osteoblasts in the metastasis of prostate cancer. Cancer Metastasis Rev 25(4):601-9, 12/2006. PMID: 17160554.
5. Tu SM, Lin SH. Clinical Aspects of bone metastases in prostate cancer. Cancer Treat Res 118:23-46, 2004. PMID: 15043187.
6. Logothetis C, Tu SM, Navone N. Targeting prostate cancer bone metastases. Cancer 97(3 Suppl):785-8, 2/2003. PMID: 12548576.

Book Chapters

1. Tu SM, Kilbourn RG. A Comprehensive Review. Prostate Cancer In: Medical Oncology. In: Ed(s) R. Wittes PRR, Inc. Huntington, NY, 283-94, 1993.

Books (edited and written)

1. Tu SM. Origin of cancers. Clinical perspectives and implications of a stem-cell theory of cancer. In: Cancer Treat Res. 154, 2010. ISBN: 20645140.

Letters to the Editor

1. Tu SM, Lin SH, Logothetis C. Re: A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J Natl Cancer Inst 95(15):1174-5; author reply 1175, 8/2003. PMID: 12902452.
2. Shi-Ming Tu, Sue-Hwa Lin, Christopher Logothetis. A Randomized, Placebo-Controlled Trial of Zoledronic Acid in Patients with Hormone-Refractory Metastatic Prostate Carcinoma. J Natl Cancer Inst, 2003.

Manuals, Teaching Aids, Other Teaching Publications

1. Tu S. Disease Management of Advanced Prostate Cancer. Institute for Medical Students, 1997.

Last updated: 8/10/2016